Abstract Body

More than one million sexually transmitted infections (STIs) are acquired every day worldwide. Untreated STIs have a significant impact on the sexual and reproductive health of populations and can lead to pregnancy complications, infertility, and cancers as well as increase HIV transmission. STIs and their complications are associated with stigma and considerable social and economic consequences. Rising antimicrobial resistance, especially for gonorrhea, is seen as a major threat to global public health. The development of vaccines against a range of STI pathogens is therefore a critical public health goal. In this presentation the lessons learned from the successful development and introduction of the HPV vaccine will be reviewed. Updates on the latest evidence for simplified dosing regimens will be presented, as well as current research gaps. The vaccine development pipeline for other STIs including HSV, gonorrhea, chlamydia, syphilis, and trichomonas will be reviewed, and progress and development challenges summarized. Finally, considerations for implementation of these future vaccines will be discussed, with a focus on current evidence needs to inform future delivery strategies in a range of settings and populations, particularly in the context of rising vaccine hesitancy.